Streetbeat News

Analyst Ratings

NTLA

Intellia Therapeutics (NASDAQ:NTLA) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have adjusted their price targets, with an average target of $70.86, down from $74.86. The company faces financial challenges, including a significant revenue decline and negative profitability metrics.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 12:00 pm

AFCG

Zuanic & Associates has initiated coverage on AFC Gamma with an Overweight rating, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:53 am

NTLA

Stifel analyst Dae Gon Ha maintains a Buy rating on Intellia Therapeutics but lowers the price target from $80 to $64.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:44 am

KRYS

Stifel analyst Dae Gon Ha maintains a Buy rating on Krystal Biotech and raises the price target from $204 to $220.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:43 am

NVS

Novartis shares declined following a downgrade by B of A Securities from Buy to Neutral, with a reduced price target of $130.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:43 am

BEAM

Stifel analyst Benjamin Burnett maintains a Buy rating on Beam Therapeutics and raises the price target from $66 to $69.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:42 am

VRNA

HC Wainwright & Co. has reiterated its Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $36, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:36 am

CIVI

Piper Sandler analyst Mark Lear maintains an Overweight rating on Civitas Resources but lowers the price target from $85 to $84.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:32 am

ALLY

Morgan Stanley has maintained an Overweight rating on Ally Financial but has lowered the price target from $49 to $45.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:30 am

APP

B of A Securities has maintained a Buy rating on AppLovin and increased its price target from $100 to $120, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:14 am